玫瑰状糠疹显示COVID-19。

The Australasian journal of dermatology Pub Date : 2021-05-01 Epub Date: 2020-11-20 DOI:10.1111/ajd.13504
Stefano Veraldi, Maurizio Romagnuolo, Valentina Benzecry
{"title":"玫瑰状糠疹显示COVID-19。","authors":"Stefano Veraldi, Maurizio Romagnuolo, Valentina Benzecry","doi":"10.1111/ajd.13504","DOIUrl":null,"url":null,"abstract":"Pityriasis rosea is an acute, exanthematous disease likely caused by human herpesvirus HHV-6 and/or HHV-7. It mainly affects young adults. We present two cases of pityriasis rosea-like eruptions associated with COVID-19 infection. A 26-year-old man was admitted with a diagnosis of pityriasis rosea. The patient was in good general health and was not on therapy with systemic drugs. He stated that the rash appeared some days earlier and was accompanied by pruritus. He also complained of mild headache, weakness and arthralgia. Dermatological examination revealed several erythematous-squamous papules and plaques located mainly on the upper limbs and trunk (Fig. 1). A diagnosis of pityriasis rosea-like eruption was made. Laboratory tests (including complete blood cell, liver and renal function, inflammatory markers, syphilis serology) showed only slight increase of erythrocyte sedimentation rate. Nasal swab was positive for SARS-CoV-2. Chest X-ray was normal. Cetirizine (10 mg/day) was prescribed. The patient was followed at his home. Skin lesions and other symptoms resolved within three weeks. A 21-year-old man was admitted because of the appearance of a single infiltrated, erythematous, oval lesion located on the left hip (Fig. 2a). Mycological examination was negative. A diagnosis of herald patch of pityriasis rosea was made. No treatment was suggested. One week later, the patient returned with a widespread erythematous-squamous rash on the chest and back, with lesions of different morphology and size (Fig. 2b). The patient complained of pruritus. Furthermore, the patient reported anorexia, abdominal pain, diarrhoea and weakness. We performed nasal swab for SARS-CoV-2, which was positive. All the other laboratory examinations were within normal ranges or negative. Also, this patient was followed at home and treated with cetirizine (10 mg/day). Both the rash and symptoms subsided within three weeks. Various cutaneous manifestations have been associated with COVID-19. In addition to our cases, one other case of a pityriasis rosea-like eruption has also been reported. The cases we have described show a temporal relationship between pityriasis rosea or pityriasis rosea-like eruption and COVID-19, but they do not prove causality.","PeriodicalId":243138,"journal":{"name":"The Australasian journal of dermatology","volume":" ","pages":"e333-e334"},"PeriodicalIF":0.0000,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/ajd.13504","citationCount":"25","resultStr":"{\"title\":\"Pityriasis rosea-like eruption revealing COVID-19.\",\"authors\":\"Stefano Veraldi, Maurizio Romagnuolo, Valentina Benzecry\",\"doi\":\"10.1111/ajd.13504\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pityriasis rosea is an acute, exanthematous disease likely caused by human herpesvirus HHV-6 and/or HHV-7. It mainly affects young adults. We present two cases of pityriasis rosea-like eruptions associated with COVID-19 infection. A 26-year-old man was admitted with a diagnosis of pityriasis rosea. The patient was in good general health and was not on therapy with systemic drugs. He stated that the rash appeared some days earlier and was accompanied by pruritus. He also complained of mild headache, weakness and arthralgia. Dermatological examination revealed several erythematous-squamous papules and plaques located mainly on the upper limbs and trunk (Fig. 1). A diagnosis of pityriasis rosea-like eruption was made. Laboratory tests (including complete blood cell, liver and renal function, inflammatory markers, syphilis serology) showed only slight increase of erythrocyte sedimentation rate. Nasal swab was positive for SARS-CoV-2. Chest X-ray was normal. Cetirizine (10 mg/day) was prescribed. The patient was followed at his home. Skin lesions and other symptoms resolved within three weeks. A 21-year-old man was admitted because of the appearance of a single infiltrated, erythematous, oval lesion located on the left hip (Fig. 2a). Mycological examination was negative. A diagnosis of herald patch of pityriasis rosea was made. No treatment was suggested. One week later, the patient returned with a widespread erythematous-squamous rash on the chest and back, with lesions of different morphology and size (Fig. 2b). The patient complained of pruritus. Furthermore, the patient reported anorexia, abdominal pain, diarrhoea and weakness. We performed nasal swab for SARS-CoV-2, which was positive. All the other laboratory examinations were within normal ranges or negative. Also, this patient was followed at home and treated with cetirizine (10 mg/day). Both the rash and symptoms subsided within three weeks. Various cutaneous manifestations have been associated with COVID-19. In addition to our cases, one other case of a pityriasis rosea-like eruption has also been reported. The cases we have described show a temporal relationship between pityriasis rosea or pityriasis rosea-like eruption and COVID-19, but they do not prove causality.\",\"PeriodicalId\":243138,\"journal\":{\"name\":\"The Australasian journal of dermatology\",\"volume\":\" \",\"pages\":\"e333-e334\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1111/ajd.13504\",\"citationCount\":\"25\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Australasian journal of dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/ajd.13504\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/11/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Australasian journal of dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajd.13504","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/11/20 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 25

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pityriasis rosea-like eruption revealing COVID-19.
Pityriasis rosea is an acute, exanthematous disease likely caused by human herpesvirus HHV-6 and/or HHV-7. It mainly affects young adults. We present two cases of pityriasis rosea-like eruptions associated with COVID-19 infection. A 26-year-old man was admitted with a diagnosis of pityriasis rosea. The patient was in good general health and was not on therapy with systemic drugs. He stated that the rash appeared some days earlier and was accompanied by pruritus. He also complained of mild headache, weakness and arthralgia. Dermatological examination revealed several erythematous-squamous papules and plaques located mainly on the upper limbs and trunk (Fig. 1). A diagnosis of pityriasis rosea-like eruption was made. Laboratory tests (including complete blood cell, liver and renal function, inflammatory markers, syphilis serology) showed only slight increase of erythrocyte sedimentation rate. Nasal swab was positive for SARS-CoV-2. Chest X-ray was normal. Cetirizine (10 mg/day) was prescribed. The patient was followed at his home. Skin lesions and other symptoms resolved within three weeks. A 21-year-old man was admitted because of the appearance of a single infiltrated, erythematous, oval lesion located on the left hip (Fig. 2a). Mycological examination was negative. A diagnosis of herald patch of pityriasis rosea was made. No treatment was suggested. One week later, the patient returned with a widespread erythematous-squamous rash on the chest and back, with lesions of different morphology and size (Fig. 2b). The patient complained of pruritus. Furthermore, the patient reported anorexia, abdominal pain, diarrhoea and weakness. We performed nasal swab for SARS-CoV-2, which was positive. All the other laboratory examinations were within normal ranges or negative. Also, this patient was followed at home and treated with cetirizine (10 mg/day). Both the rash and symptoms subsided within three weeks. Various cutaneous manifestations have been associated with COVID-19. In addition to our cases, one other case of a pityriasis rosea-like eruption has also been reported. The cases we have described show a temporal relationship between pityriasis rosea or pityriasis rosea-like eruption and COVID-19, but they do not prove causality.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信